Last reviewed · How we verify
Dexamethasone Sodium Phosphate Injection, USP
At a glance
| Generic name | Dexamethasone Sodium Phosphate Injection, USP |
|---|---|
| Sponsor | Mercator MedSystems, Inc. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Dexamethasone vs. Placebo in Children and Youth Hospitalized for Orbital Cellulitis (NA)
- Evaluate the Safety of DEXYCU for the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract (PHASE4)
- Temsirolimus Alone or Paired With Dexamethasone Delivered to the Adventitia to eNhance Clinical Efficacy After Femoropopliteal Revascularization (PHASE2)
- Adaptive COVID-19 Treatment Trial 4 (ACTT-4) (PHASE3)
- Lower-Limb Adventitial Infusion of DexaMethasone Via Bullfrog to Reduce Occurrence of Restenosis After Percutaneous Transluminal Angioplasty Revascularization (PHASE2)
- Lower-Limb Adventitial Infusion of DexaMethasone Via Bullfrog to Reduce Occurrence of Restenosis After Atherectomy (ATX)-Based Revascularization (PHASE2)
- Intravenous Dexmedetomidine, Dexamethasone and Interscalene Block Duration After Arthroscopic Shoulder Surgery (PHASE4)
- IV Dexamethasone for Prolongation of Peripheral Nerve Block (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: